Explore the Agenda

8:00 am Check-In & Coffee

Track One: Opening Your First Early Access Programme

9:00 am Workshop A – EAPs 101 – Mapping Access Pathways, Programme Types & Execution Models

President & Executive Director, GARDaccess
  • Mapping early access, managed access, compassionate use, and post trial access based on how they operate, not just how they are defined
  • Distinguishing programme types and what this means for timelines, workload, and risk
  • Creating a shared, practical vocabulary that avoids misunderstanding across teams and functions

11:00 am Morning Break & Networking

11:30 am Workshop B – Setting Up & Structuring Early Access Programmes That Remain Controllable Over Time

Associate Director, Bristol Myers Squibb
  • Designing early access programme structures that align with execution capacity, internal workflows, and real-world delivery constraints
  • Making deliberate set-up decisions around eligibility, geographic scope, governance, and duration that determine how manageable a programme becomes in practice
  • Understanding how early structural choices shape future options for scaling, transitioning, reimbursement engagement, or programme closure

1:30 pm Lunch Break & Networking

2:30 pm Workshop C – Running EAPs Day to Day – Handling Operational Reality Without Losing Control

Director Evidence Operations, Oncology Business Unit Medical Evidence, AstraZeneca
  • Handling incomplete or inconsistent requests from physicians without delaying patient access unnecessarily
  • Managing grey areas, deviations, and edge cases that arise outside written procedures
  • Differentiating issues that can be progressed within existing processes from those that require escalation or rework
  • Building confidence in making pragmatic, defensible decisions while maintaining compliance and internal credibility

4:30 pm End of Workshop Day

Track Two: Advanced Challenges in Early Access Programmes

9:00 am Workshop D – Managing Early Access Programmes During War, Crisis & Systemic Disruption

Head, Medical Affairs (Growth Markets; Central Eastern Europe & Middle East & North Africa), Eisai Co., Ltd.
Associate Director, Commercial Operations & Business Intelligence, Eisai Co., Ltd.
  • Planning access continuity when supply, shipment, or legality changes abruptly due to war, sanctions, or natural disasters
  • Defining internal decision-making frameworks for when access must continue, adapt, or stop under crisis conditions
  • Managing ethical, legal, and reputational risk when patient need conflicts with external constraints
  • Establishing escalation, documentation, and communication approaches for crisis-driven access decision

11:00 am Morning Break & Networking

11:30 am Workshop E – Operationalising Informed Consent & Physician Led Responsibilities Outside Clinical Trials

Global Head of Managed Access Programs, UCB
  • Defining what “informed consent” means in treatment focused access programmes rather than research settings
  • Clarifying where sponsor responsibility ends and physician responsibility begins in non GCP environments
  • Managing variability in how consent is obtained, explained, documented, and revisited over time
  • Establishing defensible guardrails to support physicians without crossing compliance or promotional boundaries

1:30 pm Lunch Break & Networking

2:30 pm Workshop F – Running Global Access Programmes Through Distributed Execution & Shared Accountability

Associate Director, Global Medical Affairs Operations,, Deciphera Pharmaceuticals, Inc
Head of Global Access Mechanisms, Biogen
  • Designing global local operating models where execution is shared but accountability remains clear
  • Selecting, empowering, and coordinating country or regional champions without losing programme consistency
  • Managing handoffs, communication flows, and responsibilities across global teams, affiliates, and vendors
  • Aligning senior leadership on access risk, cost exposure, and long-term obligations in global portfolios

4:30 pm End of Workshop Day